Novartis backs away from once-ambitious RNAi research

Novartis ($NVS) is shuttering a large part of its once-ambitious RNAi research effort in Boston, FierceBiotech has learned. The pharma giant, which has extensive R&D operations in the Boston area, confirmed the move, saying that the lingering problems associated with delivering these therapies tied to the small number of relevant targets they could shoot for drove the move. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.